FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912367239> ?p ?o ?g. }

• W2912367239 endingPage "173.e4" @default.
• W2912367239 startingPage "166" @default.
• W2912367239 abstract "Background Vascular surgeons have a central role in managing peripheral artery disease (PAD). This study assessed their knowledge, attitudes, and behaviors regarding pharmacologic risk reduction in PAD and results were compared to a similar 2004 survey conducted by our group. Methods An online questionnaire was administered to 161 active members of the Canadian Society for Vascular Surgery. Results Forty-eight participants (30%) completed the survey. Recommended targets for low-density lipoprotein cholesterol, blood pressure, and glucose were known by 52%, 38%, and 50% of vascular surgeons, respectively. Almost all participants recognized antiplatelet dosages and statin indications, but less than half could identify indications (29%) and precautions (44%) for angiotensin converting enzyme (ACE) inhibitor therapy. A majority (58%) routinely evaluate risk factors in <50% of their patients. Most vascular surgeons regularly provide risk reduction counseling, but less than 10% initiate or modify antihypertensive or ACE inhibitor therapy. Compared to 2004, knowledge of targets and indications/precautions for common cardiovascular medications and frequency of risk factor assessment have not changed. Rates of counseling for diabetes control and statin prescription have improved, but remain suboptimal. Regarding newer medications with cardiovascular benefit, less than 10% would prescribe proprotein convertase subtilisin/kexin type 9 and sodium-glucose cotransporter 2 inhibitors if they were available. The majority of vascular surgeons rate their PAD risk reduction knowledge as average and support an up-to-date Canadian PAD guideline. Most participants believe that risk reduction therapy is best provided by family physicians and internists, but also acknowledge that vascular surgeons should be well-versed in assessing and managing risk factors in PAD. Conclusions Significant knowledge and action gaps exist among Canadian vascular surgeons with regards to pharmacologic cardiovascular risk reduction in PAD. Although there is recognition that vascular surgeons are central to the medical management of patients with PAD, few routinely evaluate risk factors and prescribe medications. There is little evidence of sufficient improvement since 2004. New educational and clinical strategies are needed to improve PAD risk reduction pharmacotherapy among Canadian vascular surgeons. Vascular surgeons have a central role in managing peripheral artery disease (PAD). This study assessed their knowledge, attitudes, and behaviors regarding pharmacologic risk reduction in PAD and results were compared to a similar 2004 survey conducted by our group. An online questionnaire was administered to 161 active members of the Canadian Society for Vascular Surgery. Forty-eight participants (30%) completed the survey. Recommended targets for low-density lipoprotein cholesterol, blood pressure, and glucose were known by 52%, 38%, and 50% of vascular surgeons, respectively. Almost all participants recognized antiplatelet dosages and statin indications, but less than half could identify indications (29%) and precautions (44%) for angiotensin converting enzyme (ACE) inhibitor therapy. A majority (58%) routinely evaluate risk factors in <50% of their patients. Most vascular surgeons regularly provide risk reduction counseling, but less than 10% initiate or modify antihypertensive or ACE inhibitor therapy. Compared to 2004, knowledge of targets and indications/precautions for common cardiovascular medications and frequency of risk factor assessment have not changed. Rates of counseling for diabetes control and statin prescription have improved, but remain suboptimal. Regarding newer medications with cardiovascular benefit, less than 10% would prescribe proprotein convertase subtilisin/kexin type 9 and sodium-glucose cotransporter 2 inhibitors if they were available. The majority of vascular surgeons rate their PAD risk reduction knowledge as average and support an up-to-date Canadian PAD guideline. Most participants believe that risk reduction therapy is best provided by family physicians and internists, but also acknowledge that vascular surgeons should be well-versed in assessing and managing risk factors in PAD. Significant knowledge and action gaps exist among Canadian vascular surgeons with regards to pharmacologic cardiovascular risk reduction in PAD. Although there is recognition that vascular surgeons are central to the medical management of patients with PAD, few routinely evaluate risk factors and prescribe medications. There is little evidence of sufficient improvement since 2004. New educational and clinical strategies are needed to improve PAD risk reduction pharmacotherapy among Canadian vascular surgeons." @default.
• W2912367239 created "2019-02-21" @default.
• W2912367239 creator A5000682755 @default.
• W2912367239 creator A5012004173 @default.
• W2912367239 creator A5013798730 @default.
• W2912367239 creator A5020734676 @default.
• W2912367239 creator A5021289101 @default.
• W2912367239 creator A5023607347 @default.
• W2912367239 creator A5024533924 @default.
• W2912367239 creator A5080334509 @default.
• W2912367239 date "2019-07-01" @default.
• W2912367239 modified "2023-10-16" @default.
• W2912367239 title "Perceptions of Canadian Vascular Surgeons Toward Pharmacologic Risk Reduction in Patients with Peripheral Artery Disease: 2018 Update" @default.
• W2912367239 cites W180946569 @default.
• W2912367239 cites W1964491153 @default.
• W2912367239 cites W1967747089 @default.
• W2912367239 cites W1974653698 @default.
• W2912367239 cites W1975555310 @default.
• W2912367239 cites W1996461319 @default.
• W2912367239 cites W2019316533 @default.
• W2912367239 cites W2020547160 @default.
• W2912367239 cites W2024352468 @default.
• W2912367239 cites W2033703944 @default.
• W2912367239 cites W2050953909 @default.
• W2912367239 cites W2066353814 @default.
• W2912367239 cites W2077878878 @default.
• W2912367239 cites W2083291499 @default.
• W2912367239 cites W2105674008 @default.
• W2912367239 cites W2110101054 @default.
• W2912367239 cites W2121836711 @default.
• W2912367239 cites W2123874951 @default.
• W2912367239 cites W2140136269 @default.
• W2912367239 cites W2142164422 @default.
• W2912367239 cites W2144537167 @default.
• W2912367239 cites W2144985796 @default.
• W2912367239 cites W2149540677 @default.
• W2912367239 cites W2161411270 @default.
• W2912367239 cites W2315630371 @default.
• W2912367239 cites W2323489498 @default.
• W2912367239 cites W2328116877 @default.
• W2912367239 cites W2594110291 @default.
• W2912367239 cites W2751884637 @default.
• W2912367239 cites W2768588165 @default.
• W2912367239 cites W2770821084 @default.
• W2912367239 cites W2784985164 @default.
• W2912367239 cites W2787972950 @default.
• W2912367239 cites W2789097506 @default.
• W2912367239 cites W2804731383 @default.
• W2912367239 cites W2887712073 @default.
• W2912367239 cites W2975859535 @default.
• W2912367239 cites W4229536675 @default.
• W2912367239 cites W4233337036 @default.
• W2912367239 cites W4236265835 @default.
• W2912367239 cites W424467158 @default.
• W2912367239 cites W4297067663 @default.
• W2912367239 cites W80986181 @default.
• W2912367239 doi "https://doi.org/10.1016/j.avsg.2018.11.034" @default.
• W2912367239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30771465" @default.
• W2912367239 hasPublicationYear "2019" @default.
• W2912367239 type Work @default.
• W2912367239 sameAs 2912367239 @default.
• W2912367239 citedByCount "12" @default.
• W2912367239 countsByYear W29123672392020 @default.
• W2912367239 countsByYear W29123672392021 @default.
• W2912367239 countsByYear W29123672392022 @default.
• W2912367239 countsByYear W29123672392023 @default.
• W2912367239 crossrefType "journal-article" @default.
• W2912367239 hasAuthorship W2912367239A5000682755 @default.
• W2912367239 hasAuthorship W2912367239A5012004173 @default.
• W2912367239 hasAuthorship W2912367239A5013798730 @default.
• W2912367239 hasAuthorship W2912367239A5020734676 @default.
• W2912367239 hasAuthorship W2912367239A5021289101 @default.
• W2912367239 hasAuthorship W2912367239A5023607347 @default.
• W2912367239 hasAuthorship W2912367239A5024533924 @default.
• W2912367239 hasAuthorship W2912367239A5080334509 @default.
• W2912367239 hasConcept C126322002 @default.
• W2912367239 hasConcept C134018914 @default.
• W2912367239 hasConcept C141071460 @default.
• W2912367239 hasConcept C142724271 @default.
• W2912367239 hasConcept C177713679 @default.
• W2912367239 hasConcept C2776839432 @default.
• W2912367239 hasConcept C2777466421 @default.
• W2912367239 hasConcept C2779134260 @default.
• W2912367239 hasConcept C2780182762 @default.
• W2912367239 hasConcept C555293320 @default.
• W2912367239 hasConcept C71924100 @default.
• W2912367239 hasConceptScore W2912367239C126322002 @default.
• W2912367239 hasConceptScore W2912367239C134018914 @default.
• W2912367239 hasConceptScore W2912367239C141071460 @default.
• W2912367239 hasConceptScore W2912367239C142724271 @default.
• W2912367239 hasConceptScore W2912367239C177713679 @default.
• W2912367239 hasConceptScore W2912367239C2776839432 @default.
• W2912367239 hasConceptScore W2912367239C2777466421 @default.
• W2912367239 hasConceptScore W2912367239C2779134260 @default.
• W2912367239 hasConceptScore W2912367239C2780182762 @default.
• W2912367239 hasConceptScore W2912367239C555293320 @default.
• W2912367239 hasConceptScore W2912367239C71924100 @default.
• W2912367239 hasFunder F4320322015 @default.

• next